118 related articles for article (PubMed ID: 29027616)
1. Hormone receptor-positive invasive lobular and ductal carcinoma of the breast have comparable hormone receptor expression levels both if detected by screening and clinically.
Ravaioli A; Falcini F; Bucchi L
Breast Cancer Res Treat; 2018 Feb; 167(3):817-818. PubMed ID: 29027616
[No Abstract] [Full Text] [Related]
2. Enhanced resistance to tamoxifen by the c-ABL proto-oncogene in breast cancer.
Zhao H; Ou-Yang F; Chen IF; Hou MF; Yuan SS; Chang HL; Lee YC; Plattner R; Waltz SE; Ho SM; Sims J; Wang SC
Neoplasia; 2010 Mar; 12(3):214-23. PubMed ID: 20234815
[TBL] [Abstract][Full Text] [Related]
3. Estrogen and progesterone receptor expression levels do not differ between lobular and ductal carcinoma in patients with hormone receptor-positive tumors.
Truin W; Roumen RMH; Siesling S; van de Vijver KK; Tjan-Heijnen VCG; Voogd AC
Breast Cancer Res Treat; 2017 Jul; 164(1):133-138. PubMed ID: 28365833
[TBL] [Abstract][Full Text] [Related]
4. Population-based Study of Prosigna-PAM50 and Outcome Among Postmenopausal Women With Estrogen Receptor-positive and HER2-negative Operable Invasive Lobular or Ductal Breast Cancer.
Lænkholm AV; Jensen MB; Eriksen JO; Roslind A; Buckingham W; Ferree S; Nielsen T; Ejlertsen B
Clin Breast Cancer; 2020 Aug; 20(4):e423-e432. PubMed ID: 32253134
[TBL] [Abstract][Full Text] [Related]
5. The prevalence of estrogen receptor-1 mutation in advanced breast cancer: The estrogen receptor one study (EROS1).
Najim O; Huizing M; Papadimitriou K; Trinh XB; Pauwels P; Goethals S; Zwaenepoel K; Peterson K; Weyler J; Altintas S; van Dam P; Tjalma W
Cancer Treat Res Commun; 2019; 19():100123. PubMed ID: 30826563
[TBL] [Abstract][Full Text] [Related]
6. Quantitative hormone receptor (HR) expression and gene expression analysis in HR+ inflammatory breast cancer (IBC) vs non-IBC.
Iwase T; Harano K; Masuda H; Kida K; Hess KR; Wang Y; Dirix L; Van Laere SJ; Lucci A; Krishnamurthy S; Woodward WA; Layman RM; Bertucci F; Ueno NT
BMC Cancer; 2020 May; 20(1):430. PubMed ID: 32423453
[TBL] [Abstract][Full Text] [Related]
7. Specific sites of metastases in invasive lobular carcinoma: a retrospective cohort study of metastatic breast cancer.
Inoue M; Nakagomi H; Nakada H; Furuya K; Ikegame K; Watanabe H; Omata M; Oyama T
Breast Cancer; 2017 Sep; 24(5):667-672. PubMed ID: 28108967
[TBL] [Abstract][Full Text] [Related]
8. HER2-Positive Lobular Versus Ductal Carcinoma of the Breast: Pattern of First Recurrence and Molecular Insights.
Da Ros L; Moretti A; Querzoli P; Pedriali M; Lupini L; Bassi C; Carcoforo P; Negrini M; Frassoldati A
Clin Breast Cancer; 2018 Oct; 18(5):e1133-e1139. PubMed ID: 29759595
[TBL] [Abstract][Full Text] [Related]
9. [Receptor (ER, PgR) levels as prognostic factors in the endocrine therapy of pre- and post-menopausal patients with stage III infiltrative ductal and lobular cancer of the breast].
Calzada L; Salazar EL; Pedron Nuevo N
Ginecol Obstet Mex; 1996 Mar; 64():135-9. PubMed ID: 8729191
[TBL] [Abstract][Full Text] [Related]
10. Loss of heterozygosity in tumor tissue in hormonal receptor genes is associated with poor prognostic criteria in breast cancer.
Iobagiu C; Lambert C; Raica M; Lima S; Khaddage A; Peoc'h M; Genin C
Cancer Genet; 2015 Apr; 208(4):135-42. PubMed ID: 25979597
[TBL] [Abstract][Full Text] [Related]
11. Loss of function of NF1 is a mechanism of acquired resistance to endocrine therapy in lobular breast cancer.
Sokol ES; Feng YX; Jin DX; Basudan A; Lee AV; Atkinson JM; Chen J; Stephens PJ; Frampton GM; Gupta PB; Ross JS; Chung JH; Oesterreich S; Ali SM; Hartmaier RJ
Ann Oncol; 2019 Jan; 30(1):115-123. PubMed ID: 30423024
[TBL] [Abstract][Full Text] [Related]
12. [Importance of routine pathological assessment of breast cancer].
Zheng J
Zhonghua Bing Li Xue Za Zhi; 2009 Jan; 38(1):5-7. PubMed ID: 19489217
[No Abstract] [Full Text] [Related]
13. [A case of combined noninvasive ductal and lobular carcinoma].
Nagashima S; Sakurai K; Suzuki S; Hara Y; Waga E; Iizuka M; Fuchinoue T; Hirano T; Enomoto K; Tani M; Masuda S; Amano S; Koshinaga T
Gan To Kagaku Ryoho; 2012 Nov; 39(12):2033-5. PubMed ID: 23267967
[TBL] [Abstract][Full Text] [Related]
14. Outcomes in patients with early-stage breast cancer who underwent a 21-gene expression assay.
Barcenas CH; Raghavendra A; Sinha AK; Syed MP; Hsu L; Patangan MG; Chavez-MacGregor M; Shen Y; Hortobagyi GH; Valero V; Giordano SH; Ueno NT; Tripathy D
Cancer; 2017 Jul; 123(13):2422-2431. PubMed ID: 28199747
[TBL] [Abstract][Full Text] [Related]
15. Impact of 21-Gene Breast Cancer Assay on Treatment Decision for Patients with T1-T3, N0-N1, Estrogen Receptor-Positive/Human Epidermal Growth Receptor 2-Negative Breast Cancer: Final Results of the Prospective Multicenter ROXANE Study.
Dieci MV; Guarneri V; Zustovich F; Mion M; Morandi P; Bria E; Merlini L; Bullian P; Oliani C; Gori S; Giarratano T; Orvieto E; Griguolo G; Michieletto S; Saibene T; Del Bianco P; De Salvo GL; Conte P;
Oncologist; 2019 Nov; 24(11):1424-1431. PubMed ID: 31152079
[TBL] [Abstract][Full Text] [Related]
16. Prevalence of hormone receptors and HER2/neu in breast cancer cases in Jordan.
Sughayer MA; Al-Khawaja MM; Massarweh S; Al-Masri M
Pathol Oncol Res; 2006; 12(2):83-6. PubMed ID: 16799708
[TBL] [Abstract][Full Text] [Related]
17. Nm-23, c-erbB-2, and progesterone receptor expression in invasive breast cancer: correlation with clinicopathologic parameters.
Nakopoulou LL; Tsitsimelis D; Lazaris AC; Tzonou A; Gakiopoulou H; Dicoglou CC; Davaris PS
Cancer Detect Prev; 1999; 23(4):297-308. PubMed ID: 10403901
[TBL] [Abstract][Full Text] [Related]
18. Measurement of ER and PR status in breast cancer using the QuantiGene2.0 assay.
Chae BJ; Bae JS; Yim HW; Lee A; Song BJ; Jeon HM; Chun MH; Jung SS
Pathology; 2011 Apr; 43(3):248-53. PubMed ID: 21436635
[TBL] [Abstract][Full Text] [Related]
19. ESR1 and PGR gene promoter methylation and correlations with estrogen and progesterone receptors in ductal and lobular breast cancer.
Medina-Jaime AD; Reyes-Vargas F; Martinez-Gaytan V; Zambrano-Galvan G; Portillo-Delcampo E; Burciaga-Nava JA; Reyes-Romero M; Sifuentes-Alvarez A
Asian Pac J Cancer Prev; 2014; 15(7):3041-4. PubMed ID: 24815444
[TBL] [Abstract][Full Text] [Related]
20. Factors influencing the hormone receptor and HER2 levels in breast cancer: a population-based analysis.
Tas F
Onkologie; 2012; 35(3):95-8. PubMed ID: 22414972
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
